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Since the identification of the hepatitis C virus
(HCV) as the most common etiologic agent of
posttransfusion and sporadic non-A, non-B hepa-
titis [1, 2], important aspects of the epidemiology,
molecular virology, and natural course of hepatitis
C have been elucidated. In addition, specific and
sensitive assays for the diagnosis of HCV infection
have been developed. However, important aspects
of the molecular biology of HCV, the pathogene-
sis of HCV-induced liver disease as well as many
therapeutic and preventive issues are still unre-
solved. In the following, we will briefly review cur-
rent understanding of the epidemiology, molecu-
lar biology, pathogenesis, and natural history of
HCV infection as well as give an update of the di-
agnosis, therapy, and prevention of hepatitis C.
Hepatitis C virus (HCV) infection is a leading
cause of chronic hepatitis, liver cirrhosis, and he-
patocellular carcinoma worldwide. While current
therapeutic options for hepatitis C are limited, re-
cent progress in the understanding of the biology
of HCV led to the identification of novel targets
for antiviral intervention. In addition, molecular
and immunotherapeutic strategies to inhibit HCV
replication or gene expression and to enhance the
cellular immune response against HCV are being
explored. These and other novel antiviral strate-
gies may eventually complement existing thera-
peutic modalities. Here, we briefly review current
concepts of the epidemiology, molecular virology,
pathogenesis, natural history, diagnosis, therapy,
and prevention of hepatitis C.
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Summary
Introduction
Epidemiology
It is estimated that about 170 million people
worldwide are infected with HCV [3]. The sero-
prevalence rate is about 1% in Western Europe
and North America, 3–4% in some Mediterranean
and Asian countries and up to 10–20% in parts of
Central Africa and Egypt [4, 5]. In Switzerland an
estimated 50,000 to 70,000 individuals are HCV-
infected [6]. HCV is parenterally transmitted.
With the introduction of anti-HCV screening of
blood and blood products in 1990 new cases of
posttransfusion hepatitis C have virtually disap-
peared and intravenous drug use has become the
major identifiable mode of transmission in many
countries. Unfortunately, the lack of systematic
screening of blood donors continues to result in
HCV transmission in countries with developing or
transitional economies. In addition, large-scale
immunization and parenteral therapy programs as
well as surgical and dental procedures with inade-
quately sterilized equipment have been important
routes of transmission in these countries [7]. HCV
transmission has been described in nosocomial set-
tings, including organ transplantation [8]. Occu-
pational needle-stick injuries from anti-HCV pos-
itive sources result in seroconversion in about 3%
of recipients; thus representing a transmission risk
between that of HIV (about 0.3%) and hepatitis B
virus (HBV) (about 30% in unvaccinated recipi-
ents). Intranasal cocaine use has been identified as
a possible mode of transmission (“straw sharing”)
[9]. Sexual transmission is rare and correlates with
high-risk sexual practices. Mother-to-infant trans-
mission has been observed, but the risk is proba-
bly less than 5% unless the mother is co-infected
with HIV. There is no proven association between
transmission and the type of delivery or maternal
breast-feeding. Household transmission is uncom-
mon. Intriguingly, in clinical practice no epidemi-
ologic risk factor can be identified in up to 40% of
patients with hepatitis C (“sporadic hepatitis C”).
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Molecular virology
HCV has been classified in the Hepacivirus
genus within the Flaviviridae family of viruses
which includes the classical flaviviruses, such as
yellow fever virus and the animal pestiviruses [10].
The structure and replication cycle of HCV are in-
completely understood due to the low viral titers
found in sera and livers of HCV-infected individ-
uals and the lack of an efficient cell culture system
or small animal model permissive for HCV infec-
tion. Nevertheless, considerable progress has been
made using heterologous expression systems,
functional cDNA clones, and most recently, selec-
table subgenomic replicons [11–15].
HCV contains a single-stranded RNA genome
of positive polarity and approximately 9,600 nu-
cleotides. As in flavi- and pestiviruses, the viral
genome is composed of a 5’ noncoding region (5’
NCR), a long open reading frame encoding a
polyprotein precursor of about 3,000 amino acids,
and a 3’ NCR (figure 1). The 5’ NCR functions as
an internal ribosomal entry site (IRES) essential
for cap-independent translation of the viral RNA.
The HCV polyprotein precursor is co- and post-
translationally processed by cellular and viral pro-
teases to yield the mature structural and non-struc-
tural proteins. The structural proteins include the
core protein, which forms the viral nucleocapsid,
and the envelope glycoproteins E1 and E2. These
are released from the polyprotein precursor by the
endoplasmic reticulum signal peptidase.
CD81 and the low density lipoprotein recep-
tor have been proposed as HCV receptor candi-
dates or potential components of a receptor com-
plex [16, 17]. Presently, however, these molecules
do not fulfill the criteria of a bona fide viral recep-
tor and the search for other candidates is going on.
E2 has recently been reported to interfere with the
catalytic activity of the interferon (IFN)-induced
Figure 1
Genetic organization
and polyprotein pro-
cessing of HCV. As-
terisks in the E1 and
E2 region indicate
glycosylation of the
envelope proteins.
Diamonds denote
cleavages of the HCV
polyprotein precursor
by the endoplasmic
reticulum signal pep-
tidase, and arrows
indicate cleavages by
HCV NS2-3 and NS3
proteases.
Figure 2
Structure of the HCV RNA-dependent RNA
polymerase. A model for a polymerase-RNA
template: primer-rNTP complex is shown. (A)
The completely encircled pathway for access 
of the rNTP to the active site is shown. The mo-
lecular surface is colored from blue (positive)
to red (negative) according to the local electro-
static surface potential. (B) Ribbon diagram
with the fingers subdomain drawn in blue, the
palm subdomain in red and the thumb sub-
domain in green (from Lesburg CA et al. Nat
Struct Biol 1999;6:937–943 with permission
from Patricia C. Weber, Ph.D. and the Nature
Publishing Group, New York, NY, USA).
double-stranded RNA-activated protein kinase
PKR [18]. The significance of this observation,
however, for the IFN resistance commonly ob-
served in clinical practice is unclear [19].
The non-structural proteins NS2 through
NS5 include the NS2–3 autoprotease and the NS3
serine protease, which are essential for processing
of the polyprotein precursor, a RNA helicase lo-
cated in the carboxy-terminal region of NS3, the
NS4A polypeptide, the NS4B and NS5A proteins,
and a RNA-dependent RNA polymerase repre-
sented by NS5B (figure 1). The crystal structures
of the serine protease and RNA helicase domains
of NS3, and more recently, of the entire NS3 pro-
tein [20] as well as the RNA-dependent RNA poly-
merase have been elucidated [21] (figure 2). These
enzymes are essential for viral replication and have
emerged as major targets for the design of novel
antiviral agents. NS4A is a cofactor for the NS3
serine protease. The functions of NS4B and
NS5A, a serine phosphoprotein, remain to be es-
tablished. Similar to E2, NS5A has been reported
to interfere with PKR function [22]. In this con-
text, a role for NS5A in modulating the IFN re-
sponse was first suggested by studies performed in
Japan, which described a correlation between mu-
tations within a discrete region of NS5A, termed
interferon sensitivity determining region (ISDR),
and a favorable response to IFN-α therapy [23].
These findings were largely confirmed in Japan,
but not in Europe and North America. The rea-
sons for this discrepancy are not understood but
may involve both differences in IFN-α regimens
and the low prevalence of ‘mutant type’ HCV
genotype 1b isolates in Western countries.
Taken together, the presumed life cycle of
HCV includes (1) binding to an as yet unidentified
cell surface receptor and internalization into the
host cell, (2) cytoplasmic release and uncoating of
the viral RNA genome, (3) IRES-mediated trans-
lation, (4) polyprotein processing by cellular and
viral proteases, (5) RNA replication, (6) packaging
and assembly, (7) virion maturation, and (8) release
from the host cell (figure 3).
Recent studies have suggested that HCV in-
fection is a highly dynamic process with a viral
half-life of only a few hours and average daily
virion production and clearance rates of up to more
than 1012 [24]. These findings are similar to the dy-
namics of HIV infection and provide a rationale
for the development and implementation of mul-
tidrug combination therapies against hepatitis C.
In addition, together with the lack of a proof-read-
ing function of the viral RNA-dependent RNA
polymerase, this high replicative activity provides
the basis for the genetic variability of HCV. 
HCV isolates fall into 3 major categories, de-
pending on the degree of sequence divergence:
genotypes, subtypes, and isolates [25]. The term
quasispecies refers to the genetic heterogeneity of
the population of HCV genomes coexisting in an
infected individual. Genotypes 1–3 have a world-
wide distribution, genotypes 4 and 5 are found
principally in Africa and genotype 6 is distributed
primarily in Asia. Several studies have shown that
infection with genotype 1, with a prevalence of
70–80% in most Western countries, is associated
with a poor response to IFN-α therapy [26, 27].
More recently, it was proposed to divide HCV
isolates into 6 phylogenetically distinct groups,
termed clades 1 to 6 [28]. Clades 1, 2, 4, and 5 cor-
respond to genotypes 1, 2, 4, and 5 while clade 3
comprises genotypes 3 and 10, and clade 6 com-
prises genotypes 6, 7, 8, 9, and 11.
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Figure 3
HCV life cycle. (1)
Virus binding and in-
ternalization, (2) cyto-
plasmic release and
uncoating, (3) IRES-
mediated translation,
(4) polyprotein pro-
cessing, (5) RNA
replication, (6) pack-
aging and assembly,
(7) virion maturation,
(8) virion release.
Figure 4
Natural course 
of hepatitis C.
Acute hepatitis Chronic hepatitis Cirrhosis HCC
70–80% 20% 1–4% per year
The mechanisms responsible for liver injury in
acute and chronic HCV infection are poorly un-
derstood [29]. In primary HCV infection, liver cell
damage coincides with the development of the
host immune response and not with infection and
viral replication. In addition, persistent viral repli-
cation often occurs without evidence of liver cell
damage, suggesting that HCV is not directly cyto-
pathic. The immune response against HCV, there-
fore, plays a central role in HCV pathogenesis.
HCV infection does not induce protective im-
munity. Re- and superinfection with homologous
and heterologous isolates has been shown in both
experimental and clinical studies [30, 31]. The role
of antibodies in immunopathology has not been
studied in much detail so far. HCV-specific major
histocompatibility complex (MHC) class I-re-
stricted CD8+ cytotoxic T lymphocyte (CTL) [32,
33] and MHC class II-restricted CD4+ helper T
cell responses [34, 35] have been identified in pa-
tients with acute and chronic HCV infection.
CTL-mediated lysis of virus-infected host cells
may lead to clearance of the virus or, if incomplete,
to viral persistence and eventually chronic hepati-
tis. Based on these observations and parallels in
other viral diseases, viral persistence and immuno-
logically mediated liver cell injury are important
mechanisms leading to chronic hepatitis C [29].
Patients who clear HCV infection have a more
vigorous CD4+ [34, 35] and CD8+ T cell response
early on [33]. Despite the presence of an immune
response, however, HCV is rarely eliminated. For
a noncytopathic virus to persist it must overwhelm,
not induce, or evade an antiviral immune response.
Perhaps the simplest explanation is quantitative,
based on the kinetics of infection relative to the in-
duction of a CTL response during the early phase
of an infection [36]. According to this model, viral
persistence would be predicted if the size of the in-
oculum or the replication rate of the virus exceeds
the kinetics of the immune response. However, to
be consistent with the repeated observation that
the CTL response is less vigorous in chronically
infected patients than it is during acute self-limited
infection, additional mechanisms must be in-
volved. These may include the induction of peri-
pheral tolerance or exhaustion of the T cell re-
sponse, infection of immunologically privileged
sites, inhibition of antigen presentation, down reg-
ulation of viral gene expression and viral mutations
that abrogate, anergize or antagonize antigen
recognition by virus-specific T cells [29]. There is
some evidence that privileged sites may play a role
since HCV may infect extrahepatic cells and tis-
sues. Inhibition of antigen presentation is for some
viruses a mechanism to establish a persistent in-
fection. Thus far, however, there is no evidence for
these processes in HCV infection [37]. HCV, how-
ever, may interfere with the IFN system [18, 22,
38]. As mentioned above, the role of viral escape
mutations and the quasispecies nature of HCV as
a cause of viral persistence has attracted consider-
able interest. Molecular mimicry represents an-
other potential mechanism of viral persistence and
pathogenesis. In this context, we have recently
found that CTL induced by an HCV core-derived
synthetic peptide in some cases also recognized cy-
tochrome P450; an observation that lends support
for the hypothesis that HCV infection may be
causally linked to autoimmune hepatitis in some
patients [39].
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Pathogenesis
Natural history
After an incubation period of 3 to 12 weeks
HCV infection is usually followed by a clinically
unapparent hepatitis [40]. Only about 25% of pa-
tients are symptomatic. Fulminant hepatitis C is
very uncommon. One of the most important clin-
ical features of hepatitis C is its progression to
chronicity in about 70–80% (figure 4). Typically,
patients with chronic hepatitis C have few symp-
toms, if any, and these are usually nonspecific, in-
termittent, and mild. The most common symptom
is fatigue.
The natural history of chronic hepatitis C has
been analyzed in several retro- and prospective
studies [41]. While no increased mortality was
found in the retrospective Veterans Administra-
tion study [42], other studies indicated that chronic
hepatitis C frequently progresses to cirrhosis and
hepatocellular carcinoma (HCC) [43]. On the
other hand, recent studies on highly selected co-
horts have again shown a more benign course [44,
45]. Overall, about 20% of patients with chronic
hepatitis C will develop liver cirrhosis within ap-
proximately 20 years. Once cirrhosis is established
the rate of HCC development is 1–4% per year.
HCV infection appears to be responsible for a sub-
stantial proportion of the recently observed in-
crease in HCC incidence and mortality [46]. Al-
though recent experimental evidence raises the
possibility that HCV might operate through direct
pathways in promoting malignant transformation
of hepatocytes, it is generally believed that HCC
associated with chronic hepatitis C develops
through a general pathway of increased liver cell
turnover, induced by chronic liver injury and re-
generation, resulting in multiple and stepwise ge-
netic alterations [47]. The highly variable natural
course of chronic hepatitis C may depend on viral
(e.g., inoculum size, genotype, and quasispecies
complexity) and host factors (e.g., age at the time
of infection, gender, MHC haplotype, coinfection
with HBV or HIV, and, probably most important,
alcohol consumption).
Chronic HCV infection has been associated
with a number of extrahepatic manifestations, in-
cluding mixed cryoglobulinemia, glomeru-
lonephritis, lichen planus, and porphyria cutanea
tarda [48]. Cryoglobulins are detectable in up to
one third of patients with chronic hepatitis C,
while the clinical syndrome of mixed cryoglobu-
linemia occurs in only 1–2% of patients. Recently,
chronic hepatitis C has been associated with non-
Hodgkin’s lymphoma and type 2 diabetes mellitus.
However, these associations are still debated.
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Diagnosis
Diagnosis of hepatitis C is based on serologi-
cal assays which detect HCV-specific antibodies
(anti-HCV) and on molecular assays which detect
HCV RNA. The molecular assays currently avail-
able are reverse transcriptase (RT)-PCR and the
branched DNA (bDNA) assay. By RT-PCR the
viral RNA is reverse transcribed into complemen-
tary DNA (cDNA) that is then amplified by PCR.
In the bDNA assay the signal resulting from a spe-
cific hybridization of capture and detection probes
with the viral RNA is amplified.
Third-generation anti-HCV enzyme-linked
immunosorbent assays (ELISAs) are highly sensi-
tive as well as specific and represent the primary
diagnostic assay. Anti-HCV tests are less sensitive,
however, in immunocompromised individuals or
hemodialysis patients. For these patients, a nega-
tive ELISA does not exclude HCV infection, and
RT-PCR should be performed. The recombinant
immunoblot assay (RIBA) is a supplemental assay
that can be used to confirm a positive ELISA, par-
ticularly in low-risk populations. In this setting, a
negative RIBA will make further testing unneces-
sary. No routine serological test for a viral antigen
is available as yet. However, immunoassays based
on the use of high-affinity monoclonal antibodies
against core protein to detect and quantitate HCV
in serum are currently being evaluated [49].
HCV becomes positive by RT-PCR as early as
1–2 weeks after infection and 4-6 weeks before
anti-HCV seroconversion. The determination of
HCV RNA is, in principle, important for the se-
lection of patients for antiviral therapy and for the
assessment of its efficacy [27]. Optimal RT-PCR
assays at present have a sensitivity of less than 100
copies of HCV RNA per ml of plasma or serum.
Standardization of assays and proficiency testing of
diagnostic laboratories has recently improved the
previously high rate of false-positive and -negative
PCR results. In the case of a positive ELISA, RT-
PCR allows to discriminate between patients with
chronic hepatitis C and those with resolved HCV
infection that can remain anti-HCV positive for
years or decades. Intriguingly, recent studies have
shown that the antibody response to HCV fades
over time in many patients after successful elimi-
nation of the virus [50].
Discrimination of genotype 1 from genotypes
2 and 3 as well as quantitative determination of
viremia levels has become important for the selec-
tion of the optimal treatment regimen [27]. In gen-
eral, however, genotyping and quantitative RT-
PCR tests should be used only in the context of 
a defined therapy protocol and not for the initial
diagnosis of HCV infection.
Liver biopsy allows to determine the necro-in-
flammatory activity (grading) and the degree of fi-
brosis (staging), as well as to recognize or exclude
coexisting liver pathology (such as alcoholic liver
disease or hemochromatosis). It is strongly rec-
ommended before the initiation of antiviral ther-
apy.
Current therapy
The decision to treat is based on the analysis
of numerous variables and should take into ac-
count the specific situation of each patient. In gen-
eral, treatment is currently recommended for pa-
tients with persistently (>6 months) elevated
aminotransferase levels, anti-HCV and RNA pos-
itivity in serum, and findings of fibrosis and at least
moderate degrees of inflammation and necrosis on
liver biopsy [26, 27]. For other patients the in-
dications are less clear and decisions will have to
be made on an individual basis. Additional factors
that come into consideration are, among others,
the age and general condition of the patient, the
duration of HCV infection, the risk of developing
cirrhosis, the likelihood of response to therapy,
comorbidity, and the patient’s personal and pro-
fessional plans. Importantly, impairment of qual-
ity of life during treatment should be taken into
account and discussed with the patient. Contra-
indications to therapy with IFN and ribavirin in-
clude decompensated liver cirrhosis, autoimmune
hepatitis or other autoimmune diseases, a history
of depression or psychosis, pregnancy, the lack of
a reliable method of contraception (teratogenicity
of ribavirin), cardiopulmonary diseases, leukope-
nia (<2,000/µl), thrombocytopenia (<50,000/µl),
and conditions that impair compliance with ther-
apy.
Current standard therapy consists of the sub-
cutaneous application of 3 million units IFN-α 3
times per week combined with the oral application
of 1000 to 1200 mg ribavirin per day. Patients in-
fected with genotype 1 should be treated for 12
months and patients with genotype 2 and 3 for 6
months [27]. The most frequent adverse effect of
ribavirin is hemolytic anemia that may require
dose reduction or discontinuation of treatment.
IFN-α and ribavirin may operate through direct
antiviral and immunomodulatory mechanisms [51,
52].
Patients who become HCV RNA negative
during therapy and remain so for more than 6
months after the end of treatment have a sustained
response and usually remain negative [53]. Patients
who are HCV RNA negative at the end of treat-
ment but become positive again at 6 months of fol-
low-up are classified as relapsers. Relapsers of IFN
monotherapy should be retreated with combina-
tion therapy [54]. There is no established therapy
for nonresponders. These patients should be re-
ferred to specialized centers and treated only
within controlled clinical trials. Favorable results
with a triple therapy consisting of IFN-α, rib-
avirin, and amantadine need to be reproduced in
larger trials [55]. A variety of alternative agents
have been or are being evaluated in clinical trials,
either as monotherapy or in combination with
IFN-α. These include, among others, antioxidants
and sulfhydryl donors such as vitamin E and 
N-acetyl cysteine, immunomodulators such as
levamisole and thymosin α-1, ursodeoxycholic
acid, nonsteroidal anti-inflammatory drugs, pen-
toxifylline, glycyrrhizin, and various herbal reme-
dies including milk thistle, which contains the he-
patoprotective agent silymarin. Controlled clinical
trials will hopefully clarify whether any of these
agents will be useful for the treatment of chronic
hepatitis C.
Recently, significantly increased sustained re-
sponse rates as compared to conventional IFN-α
monotherapy have been achieved with poly-
ethylenglycol (PEG)-conjugated IFN-α [56, 57].
Pegylated IFNs will probably replace the conven-
tional IFNs in the near future because they are
more effective and have to be injected only once
weekly due to their prolonged half-life. Sustained
response rates achieved with PEG-IFN-α
monotherapy range from 35 to 40%, which is sim-
ilar to the response to combination therapy with
conventional IFN-α and ribavirin. There is now
legitimate hope that combination therapy with
PEG-IFN-α and ribavirin will have even higher
sustained response rates, but the results of large,
prospective, randomized controlled trials will have
to be awaited.
HCV-infected patients with persistently nor-
mal transaminases should not be treated. The ben-
efit of currently available antiviral therapy in chil-
dren or the elderly, in patients with acute hepati-
tis, in patients coinfected with HIV or HBV, and
in organ transplant recipients is not established.
These patients should be referred to a specialized
center.
Liver cirrhosis due to chronic hepatitis C is the
leading indication for liver transplantation in many
Western countries including Switzerland. This is
inevitably followed by recurrent infection of the al-
lograft. However, in contrast to hepatitis B, recur-
rent hepatitis C is typically mild and only slowly
progressive [58].
In view of the rapidly evolving therapeutic op-
tions, the practicing physician who treats and fol-
lows patients with chronic hepatitis C is encour-
aged to consult on a regular basis with a special-
ized center or institutions such as the Swiss Asso-
ciation for the Study of the Liver (www.sasl.ch) or
the Swiss Board of Experts for Viral Hepatitis
(www.sevhep.unizh.ch).
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Evolving therapeutic strategies
The rapidly increasing knowledge of the HCV
replication cycle provides opportunities for the de-
velopment of innovative therapeutic and preven-
tive strategies. In principle, each of the steps illus-
trated in figure 3 represents a target for antiviral
intervention [59]. As outlined above, specific in-
hibitors of the biochemically and structurally well-
characterized NS3 serine protease, the RNA heli-
case and the RNA-dependent RNA polymerase,
are currently being developed as antiviral agents.
A polymerase inhibitor, VP 50406, is now in phase
II clinical trial and many more will likely follow
soon [60]. In addition to these more classical phar-
macological approaches, gene therapeutic strate-
gies aimed at inhibiting HCV replication and gene
expression are currently being explored in various
experimental systems [61]. These include, among
others, antisense oligodeoxynucleotides and ri-
bozymes. In this context, the first anti-HCV ri-
bozyme has now entered phase II clinical testing
[62]. Moreover, based on the concept that a quan-
titatively and qualitatively insufficient CD4+ and
CD8+ T cell response may contribute to viral per-
sistence, immunotherapeutic strategies aimed at
enhancing the cellular immune response against
HCV are currently being investigated (see below).
Apart from more efficient therapeutic strate-
gies, the development and implementation of pre-
ventive measures are of paramount importance.
The development of an effective recombinant vac-
cine has been hampered by the high genetic vari-
ability of HCV and the lack of a suitable cell cul-
ture system or small animal model. It has been
shown, however, that vaccination with recombi-
nant envelope proteins expressed in mammalian
cells can protect chimpanzees from primary infec-
tion with a homologous virus isolate [63]. How-
ever, the correlates of and requirements for a
broader protection and a potentially neutralizing
immune response still need to be defined. The po-
tential of DNA vaccination to induce a humoral
and cellular immune response is particularly
promising in this regard [64]. Alternative currently
pursued strategies include peptide and protein vac-
cines, dendritic cell-based vaccines, and virus-like
particles. While sterilizing immunity will probably
be difficult to achieve, the aim of inducing a state
of immunity that prevents the development of
chronic infection appears more realistic [65]. In
any case, it is likely that induction of both a hu-
moral and a cellular immune response will be re-
quired for an effective HCV vaccine. Such a vac-
cine may be used also as a therapeutic vaccine. In
this context, a phase II clinical trial based on a re-
combinant HCV E1 vaccine will soon be initiated
in patients with chronic hepatitis C [66].
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Vaccine development
Perspectives
Recent progress has allowed the identification
of novel antiviral targets and therapeutic strategies
for hepatitis C. These may complement the exist-
ing therapeutic modalities in the future. Much
work remains to be done with respect to HCV
virion structure, the early and late steps of the viral
life cycle, and the pathogenesis of HCV-induced
liver disease. Progress in these directions will de-
pend, among others, on the development of effi-
cient cell culture systems and suitable small animal
models of hepatitis C. Ultimately, an improved un-
derstanding of the viral life cycle should result in
innovative therapeutic and preventive strategies
for one of the most common causes of chronic hep-
atitis, liver cirrhosis, and HCC worldwide.
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